Premium
Doubling time of serum CA 19‐9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis
Author(s) -
Nishida Koichi,
Kaneko Toshiro,
Yoneda Mitsuru,
Nakagawa Shuji,
Ishikawa Takeshi,
Yamane Etsuo,
Nishioka Bunzo,
Miyamoto Yuji,
Takano Hirohisa,
Yoshikawa Toshikazu,
Kondo Motoharu
Publication year - 1999
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/(sici)1096-9098(199907)71:3<140::aid-jso2>3.0.co;2-t
Subject(s) - doubling time , medicine , pancreatic cancer , metastasis , cancer , oncology , disease , gastroenterology , cell , genetics , biology
Background and Objectives Pancreatic cancer is generally a disease with a poor prognosis, and relationship between change of serum CA 19‐9 level and progression of this disease was investigated with regard to clinical pace of disease and tumor growth. Methods CA 19‐9 doubling time was examined in 75 patients with pancreatic cancer, including 41 inoperable cases. Then, its relation with their prognosis and change in tumor was evaluated. Results The doubling time of CA 19‐9 and CEA could be calculated in 90.2% and 58.5% of patients with inoperable pancreatic cancer. CA 19‐9 doubling time was clearly associated with survival time in inoperable and palliatively operated cases, but not with sex, age, site of the lesion, or liver metastasis, and was significantly correlated with the tumor volume doubling time. Conclusions Examination of CA 19‐9 doubling time may be useful in clinical evaluation of the prognosis for patients with pancreatic cancer and could possibly prove valuable in terms of the analysis of the growth process in this disease. J. Surg. Oncol. 1999;71:140–146. © 1999 Wiley‐Liss, Inc.